What is the best medicine for smolder multiple myeloma?
The drug lenalidomide (Revlimid) may delay the development of multiple myeloma in individuals with smoldering myeloma that is at high risk of progressing to cancer, according to preliminary results from a clinical trial.
Is dexamethasone used for multiple myeloma?
Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.
What is second line treatment for multiple myeloma?
Second-line therapy may involve: daratumumab, bortezomib and dexamethasone. lenalidomide and dexamethasone. carfilzomib and dexamethasone.
How long can a person live with smoldering myeloma?
Among patients with progression of smoldering multiple myeloma, 97% had progression to active multiple myeloma. Rates of death owing to other diseases, including cardiovascular and cerebrovascular disease and non–plasma-cell cancers, were 18% at 5 years, 26% at 10 years, 30% at 15 years, and 35% at 20 years.
How long can smoldering myeloma last?
If two of these are present, a patient has intermediate risk smoldering myeloma with an average between 3-5 years to progression to symptomatic myeloma. The intermediate risk has an average time of between 3 and 5 years to progression.
How long does it take for dexamethasone to work?
Given by injection, dexamethasone will begin working quickly. Taken by mouth as a tablet, the effects may take from one hour up to several hours.
Can Revlimid delay the development of multiple myeloma?
CC BY 3.0 US. The drug lenalidomide (Revlimid) may delay the development of multiple myeloma in individuals with smoldering myeloma that is at high risk of progressing to cancer, according to preliminary results from a clinical trial.
Can lenalidomide slow the progression of smoldering myeloma?
In the NCI-supported clinical trial, researchers found that lenalidomide—which is already used to treat multiple myeloma—may delay or slow the progression of smoldering myeloma. Individuals who received the drug had a reduced risk of developing multiple myeloma within 3 years
What is the standard of care for smoldering multiple myeloma?
List of authors. Luis Palomera, M.D., Ph.D., For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention.
What is the reason for discontinuing treatment for multiple myeloma (MM)?
Treatment was discontinued on withdrawal of patient consent, progression to symptomatic disease, or the occurrence of unacceptable toxic effects. The study was designed by the Spanish Myeloma Group (PETHEMA/GEM), which sponsored the trial with an unrestricted grant from Celgene.